Blog

Albert Labs Files US Provisional Patent Application for Psilocybe And Other Mycelia

Jul 13 • 3 min read

Albert Labs International Corp. (CSE: ABRT | FSE: VB50), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines, based on mycelia of Psilocybe and other fungi, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a proprietary process. Albert Labs’ culturing process can…

Filament Health Issued Third Patent by United States Patent and Trademark Office

Jul 13 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a third patent by the United States Patent and Trademark Office for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming…

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Jul 12 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (“CKD”) research program with NP-251 (“Repirinast”). In Q1 2022, the Company announced that it had initiated a new CKD research program to investigate Repirinast as part of…

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Jul 11 • 3 min read

-Cybin Inc. (NEO: CYBN | NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a Phase 1 N,N-dimethyltryptamine study from Entheon Biomedical Corp. (CSE: ENBI | OTCQB: ENTBF | FSE: 1XU1). This DMT study, which is the…

Season One of the Psychedelic Invest Podcast is Now Available on YouTube

Jul 11 • 2 min read

After ten informative episodes, season one of the Psychedelic Invest Podcast is wrapped and ready for the many future listeners that are exploring this exciting industry. Considering Psychedelic Invest’s mission to educate the masses to push this industry forward, we want to make all of our content as accessible as possible. This not only means…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538